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Gila monster venom (l-300 pg/ml) is shown to inhibit completely the binding of [‘251]VIP to human and 
rat intestinal epithelial cell membranes. In both models, the venom inhibits [“‘I]VIP binding and 
stimulates adenylate cyclase with a maximal efficiency that is similar to that of VIP and a potency that 
is 10000-50000 times lower than that of the peptide, on a weight basis. At maximal doses, VIP and Gila 
monster venom do not exert an additive effect on adenylate cyclase, suggesting that the activation of the 
enzyme by the venom occurs through VIP receptors. As is the case for VIP, adenylate cyclase activation 
by Gila monster venom requires the presence of GTP in the incubation medium. Finally, no VIP-like 
immunoreactivity was detected in the venom using an antiserum raised against mammalian VIP. All these 
data suggest he presence in the venom of the Gila monster, of a new substance which behaves as a VIP 
agonist in human as well as rat intestine. 
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1. INTRODUCTION 
Many peptides have been discovered and/or 
detected in non-mammalian species and found to 
be active in mammalian biological systems [l]. 
This includes the pancreatic and/or intestinal 
secretagogues present in amphibian skin [2] or in 
scorpion venom [3,4]. In a recent report, the 
venom of Gila monster (family Helodermatidae) 
was shown to stimulate amylase secretion and 
cyclic AMP production in guinea pig pancreatic 
acini [5]. This action was ascribed to the interac- 
tion of a peptide present in the venom with cell sur- 
face receptors for vasoactive intestinal peptide 
and/or secretin. However, as the two types of 
receptors are present in guinea pig pancreatic 
acinar cells, the site of the venom action remains 
uncertain. We here use intestinal epithelial cells, a 
system that contains VIP but not secretin receptors 
[6], to clearly demonstrate that Gila monster 
venom stimulates adenylate cyclase activity 
through its interaction with VIP receptors. The 
study was performed by using both human colonic 
epithelial crypt membranes and rat small intestinal 
epithelial membranes, since a great species 
specificity of VIP receptors in discriminating 
among the natural VIP agonists was previously 
demonstrated [7,8]. 
2. MATERIALS AND METHODS 
Abbreviation: VIP, vasoactive intestinal peptide 
Gila monster venoms (Heloderma horridum and 
Heloderma suspecturn) were obtained from Sigma 
(St Louis, MO). VIP was purified from porcine 
duodenum [9]. EGF was a kind gift of Novo 
Research Institute (Copenhagen). Monocompetent 
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pork insulin was purchased from Novo. Mem- 
branes were prepared as in [lo] from isolated rat 
small intestinal epithelial cells (1 I] or isolated 
human colonic epithelial crypts [ 121. [“‘I]VIP 
[13], [“‘I]EGF [14] and [‘2SI]insulin [15] were 
prepared by the chloramine T method at a specific 
activity of 250 Ci/g, 160 Ci/g and 200 Ci/g, 
respectively. Studies of binding of [1251]VIP to 
membranes were conducted as in [16]. Binding of 
[“‘I]EGF and [1251]insulin were studied as in 
[14,15]. Adenylate cyclase was assayed as in [lo]. 
The radioimmunoassay of VIP was conducted as 
in [17]. 
3. RESULTS 
The Gila monster venom (H. horridum and H. 
suspecturn) inhibits the specific binding of 
[1251]VIP to epithelial cell membranes prepared 
from human colon (fig.1, bottom). The dose- 
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Fig. 1. Competitive inhibition of specific [t2’I]VIP 
binding to human colonic epithelial crypt membranes 
(bottom) and rat small intestinal epithelial membranes 
(top) by VIP, Gila monster venom from H. horridum 
(GMVh) and from H. suspectum (GMVs). Results are 
expressed as the percentage of radioactivity specifically 
bound in the absence of addition. Each point is the mean 
of triplicate determinations. Two other experiments gave 
similar results. 
response of venom (l-300 pug/ml concentration 
range; EDSO = 20pg/ml) parallels that of VIP, 
suggesting a competitive inhibition of labelled VIP 
binding by a substance present in the venom. At 
maximal venom concentration, the binding of 
[‘251]VIP to human colonic membranes is com- 
pletely suppressed. Fig.1 (top) shows that the 
venom inhibits also the binding of [“‘I]VIP to rat 
intestinal membranes with an EDSO of lOpg/ml 
similar to that observed in human intestine. On a 
weight basis, 10000-50000 times as much Gila 
monster venom (from both sources) as pure por- 
cine VIP are thus needed to achieve an identical 
effect. 
Rat intestinal epithelial cells were previously 
shown to exhibit specific insulin and epidermal 
growth factor receptors besides VIP receptors 
[14,18]. Gila monster venom (l-300 pg/ml) does 
not alter the specific binding of [“‘I]insulin nor 
[1251]EGF to their respective receptors (not 
shown), indicating the specificity of the venom ac- 
tion on VIP receptors. 
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Fig.2 Adenylate cyclase activity in human colonic 
epithelial crypt membranes (bottom) and rat small 
intestinal epithelial membranes (top) in ‘response to 
increasing concentrations of VIP, Gila monster venom 
from H. horridum (GMVh) and from H. suspecturn 
(GMVs). Each point is the mean of triplicate 
determinations. Two other experiments gave similar 
results. 
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Table 1 
Adenylate cyclase activity in human intestinal epithelial 
cell membranes 
Addition Adenylate cyclase activity 
CAMP pmol . min- ’ . mg 
protein-’ 
0 
Gila monster venom 
(100 ,&ml) 
VIP (1O-7 M) 
Gila monster venom 
(100 rg/ml) + 
VIP (1O-7 M) 
17_t 1 
95* 3 
114 * 10 
119* 5 
Membranes are incubated as in section 2. Results are the 
mean f SEM of triplicate determinations. Another 
experiment gave similar esults 
As shown in fig.2, the Gila monster venom from 
both sources is able to stimulate adenylate cyclase 
activity in human (bottom) and rat (top) intestinal 
membranes. In both species, the dose-responses of
Gila monster venom in stimulating the enzyme are 
similar with an EDSO of 20pg/ml. Likewise, the 
Gila monster venom and VIP act with the same ef- 
k- 
co -3-2-l 0 12 
CONCENTRATION 
(log yg/ml) 
Fig.3. Effect of Gila monster venom from H. horridum 
(GMVh) and from H. suspectum (GMVs) on the binding 
of [rz51]VIP to an antibody raised against mammalian 
VIP as in [ 171. Results are expressed as the percentage of 
initial binding of [1251]VIP to the antibody. Each point 
is the mean of triplicate determinations. Another 
experiment gave similar esults. 
ficiency, in rat and human tissue. The dose- 
responses of Gila monster venom in inhibiting 
[“‘I]VIP binding and in stimulating adenylate 
cyclase activity in intestinal membranes are very 
similar suggesting that a substance present in the 
venom acts on the enzyme through its interaction 
with VIP receptors. This is further supported by 
the 
(i) 
(ii) 
fact that: 
Gila monster venom like VIP [ 191 requires the 
presence of GTP to stimulate intestinal cyclase 
activity (not shown); 
Gila monster venom and VIP, tested at max- 
imally active doses do not elicit an additive 
stimulatory effect on cyclase activity (table 1). 
Such data strongly suggest hat Gila monster 
venom contains a VIP-like bioactive substance 
which behaves as a VIP agonist. However, as 
tested using an antibody raised against mam- 
malian VIP, the venom is devoid of VIP-like 
immunoreactivity (fig.3). 
4. DISCUSSION 
The present data indicate that the venom from 
H. horridum and H. suspecturn contains a 
substance that interacts specifically with VIP 
receptors in human and rat intestinal epithelium. 
This substance appears to be a full agonist of VIP 
since it is as efficient as VIP in inhibiting binding 
of [‘251]VIP to VIP receptors and in stimulating 
adenylate cyclase. Since the venom was shown to 
contain some degradative activities such as 
phospholipase AZ and proteolytic activities [20], 
the question whether it interacts with VIP recep- 
tors by destroying them has to be evoked. Our 
data, indicating that the venom does not alter the 
binding of [1251]insulin and [12’I]EGF to their 
specific receptors make such hypothesis very 
unlikely. The venom thus may contain a VIP-like 
bioactive substance. Its high sensitivity to trypsin 
digestion strongly suggests that this substance is of 
proteic nature [5]. The comparison of the Gila 
monster venom effect in rat and human intestine 
supports the conclusion that this substance does 
not resemble the natural VIP agonists actually 
characterized including PHI, secretin and growth 
hormone-releasing factor [8]. Indeed, while rat 
and human VIP receptors present great species 
specificity regarding their ability to discriminate 
between those different peptides [8], Gila monster 
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venom appears to be recognized similarly by the 
two receptors. In that respect, the active substance 
is not yet identified but appears to be a new agonist 
of VIP. The absence of VIP-like immunoreactivity 
in the venom indicates that this VIP agonist does 
not possess the same antigenic determinant(s) as 
mammalian VIP. Whether it is a lizard VIP dif- 
ferent from mammalian VIP, or a new peptide 
synthesized specifically in the venom sacs remains 
to be determined. Likewise, whether the interac- 
tion of this substance with VIP receptors may par- 
ticipate in the toxicity of the venom is not yet 
determined. It is clear, however, that some toxic 
effects of Gila monster venom, i.e., hypotension 
and reduction of blood flow [21], resemble the 
well-known actions of VIP [22]. A definite answer 
to those questions has to wait for the purification 
and structural analysis of this new VIP-like bioac- 
tive substance. 
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